2,444 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by ING Groep NV

ING Groep NV acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,444 shares of the biopharmaceutical company’s stock, valued at approximately $972,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. iA Global Asset Management Inc. boosted its position in Alnylam Pharmaceuticals by 979.5% during the fourth quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock worth $7,070,000 after purchasing an additional 16,133 shares during the period. Perpetual Ltd bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $2,004,000. Vanguard Group Inc. boosted its position in Alnylam Pharmaceuticals by 2.0% during the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock worth $6,185,846,000 after purchasing an additional 268,313 shares during the period. Linden Advisors LP bought a new stake in Alnylam Pharmaceuticals during the third quarter worth approximately $6,550,000. Finally, Elo Mutual Pension Insurance Co boosted its position in Alnylam Pharmaceuticals by 26.5% during the third quarter. Elo Mutual Pension Insurance Co now owns 17,865 shares of the biopharmaceutical company’s stock worth $8,146,000 after purchasing an additional 3,738 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 2.2%

ALNY opened at $291.22 on Thursday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $283.10 and a 1-year high of $495.55. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The stock has a market capitalization of $38.88 billion, a price-to-earnings ratio of 79.57 and a beta of 0.29. The business has a 50 day moving average of $306.05 and a 200-day moving average of $345.14.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the prior year, the business earned ($0.44) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 96.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the completion of the transaction, the insider directly owned 9,443 shares of the company’s stock, valued at approximately $3,120,156.06. This trade represents a 19.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 7,740 shares of company stock valued at $2,420,214. 0.86% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ALNY. Bank of America reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. Wall Street Zen raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Citigroup began coverage on Alnylam Pharmaceuticals in a research report on Tuesday, May 19th. They set a “buy” rating and a $380.00 target price for the company. Canaccord Genuity Group upped their target price on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Finally, Chardan Capital reissued a “buy” rating and issued a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $463.13.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.